MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 39,441 shares, an increase of 162.5% from the December 15th total of 15,027 shares. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are sold short. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days.

MDxHealth Stock Down 0.6%

NASDAQ MDXH opened at $3.69 on Friday. MDxHealth has a 52 week low of $1.35 and a 52 week high of $5.33. The company has a market capitalization of $174.31 million, a P/E ratio of -5.76 and a beta of 1.62. The stock’s 50-day moving average price is $3.51 and its 200-day moving average price is $3.49.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $27.43 million during the quarter, compared to the consensus estimate of $24.11 million. MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. Research analysts anticipate that MDxHealth will post -1.15 EPS for the current year.

Institutional Trading of MDxHealth

Several large investors have recently bought and sold shares of the stock. FreeGulliver LLC purchased a new position in MDxHealth during the second quarter worth approximately $273,000. Calamos Advisors LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth about $305,000. GSA Capital Partners LLP purchased a new position in MDxHealth in the 3rd quarter valued at about $48,000. Jefferies Financial Group Inc. acquired a new stake in MDxHealth in the 3rd quarter worth about $53,000. Finally, Russell Investments Group Ltd. acquired a new stake in MDxHealth during the 3rd quarter worth $461,000.

Analyst Ratings Changes

A number of research firms have issued reports on MDXH. TD Cowen increased their price objective on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Lake Street Capital boosted their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Monday, December 29th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, MDxHealth presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.